229 related articles for article (PubMed ID: 38088886)
1. Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Schilsky ML; Ott P; Sandahl TD
Hepatology; 2024 May; 79(5):1065-1074. PubMed ID: 38088886
[TBL] [Abstract][Full Text] [Related]
2. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
Kirk FT; Munk DE; Swenson ES; Quicquaro AM; Vendelbo MH; Larsen A; Schilsky ML; Ott P; Sandahl TD
J Hepatol; 2024 Apr; 80(4):586-595. PubMed ID: 38081365
[TBL] [Abstract][Full Text] [Related]
3. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML; Czlonkowska A; Zuin M; Cassiman D; Twardowschy C; Poujois A; Gondim FAA; Denk G; Cury RG; Ott P; Moore J; Ala A; D'Inca R; Couchonnal-Bedoya E; D'Hollander K; Dubois N; Kamlin COF; Weiss KH;
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1092-1102. PubMed ID: 36183738
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
[TBL] [Abstract][Full Text] [Related]
5. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
[TBL] [Abstract][Full Text] [Related]
6. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
7. The effect of certain chelating compounds on the urinary excretion of copper by the rat: observations on their clinical significance.
Gibbs K; Walshe JM
Clin Sci Mol Med; 1977 Oct; 53(4):317-20. PubMed ID: 913055
[TBL] [Abstract][Full Text] [Related]
8. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
9. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
10. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.
Smirnova J; Kabin E; Järving I; Bragina O; Tõugu V; Plitz T; Palumaa P
Sci Rep; 2018 Jan; 8(1):1463. PubMed ID: 29362485
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
12. Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines.
Říha M; Karlíčková J; Filipský T; Macáková K; Hrdina R; Mladěnka P
J Inorg Biochem; 2013 Jun; 123():80-7. PubMed ID: 23563391
[TBL] [Abstract][Full Text] [Related]
13. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Walshe JM
QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy.
McQuaid A; Mason J
J Inorg Biochem; 1991 Feb; 41(2):87-92. PubMed ID: 2033396
[TBL] [Abstract][Full Text] [Related]
15. Wilson disease - currently used anticopper therapy.
Członkowska A; Litwin T
Handb Clin Neurol; 2017; 142():181-191. PubMed ID: 28433101
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.
Brewer GJ; Yuzbasiyan-Gurkan V; Johnson V; Dick RD; Wang Y
J Am Coll Nutr; 1993 Feb; 12(1):26-30. PubMed ID: 8440814
[TBL] [Abstract][Full Text] [Related]
17. Imaging copper metabolism imbalance in Atp7b (-/-) knockout mouse model of Wilson's disease with PET-CT and orally administered 64CuCl2.
Peng F; Lutsenko S; Sun X; Muzik O
Mol Imaging Biol; 2012 Oct; 14(5):600-7. PubMed ID: 22170165
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Wilson's disease: penicillamine or triene?
Kiechl SG; Willeit J; Aichner F; Felber S
Acta Neurol Scand; 1992 Feb; 85(2):154-7. PubMed ID: 1574992
[No Abstract] [Full Text] [Related]
19. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study.
Munk DE; Lund Laursen T; Teicher Kirk F; Vilstrup H; Ala A; Gormsen LC; Ott P; Damgaard Sandahl T
Sci Rep; 2022 Aug; 12(1):14714. PubMed ID: 36038585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
